Abstract:
Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, allows for improved safety and efficacy of the ADC.
Abstract:
A compound of formula (I); or a salt or solvate thereof, wherein: the dotted line indicates the optional presence of a double bond between C2 and C3; R 2 is selected from -H, -OH, =0, =CH 2 , -CN, -R, OR, halo, =CH-R, O-SO 2 -R, CO 2 R and COR; R 7 is selected from H, R, OH, OR, SH, SR, NH 2 , NHR, NRR', nitro, Me 3 Sn and halo, where R and R' are independently selected from optionally substituted C 1-7 alkyl, C 3-20 heterocyclyl and C 5-20 aryl groups; R 10 and R 11 either together form a double bond, or are selected from H and YR Y , where Y is selected from O, S and NH and R Y is H or C 1-7 alkyl or H and SO x M, where x is 2 or 3, and M is a monovalent pharmaceutically acceptable cation; each X is independently a heteroarylene group; n is from 1 to 6; and R E is C 1-4 alkyl. The compound is useful for the treatment of proliferative diseases.
Abstract translation:式(I)化合物; 或其盐或溶剂合物,其中:虚线表示在C2和C3之间任选存在双键; R 2选自-H,-OH,= O,= CH 2,-CN,-R,OR,卤素,= CH-R,O-SO R 2和R 2,R 2和R C; R 7选自H,R,OH,OR,SH,SR,NH 2,NHR,NRR',硝基,Me 3 Sn和卤素,其中R和R'独立地选自任选取代的C 1-7 - 烷基,C 3-20 - 杂环基和C 5-20 - SUB>芳基; R 10和R 11一起形成双键,或选自H和YR Y,其中Y选自O,S 和NH和R Y是H或C 1-7烷基或H和SO x M,其中x是2或3,M 是一价药学上可接受的阳离子; 每个X独立地是亚杂芳基; n为1至6; 并且R E是C 1-4烷基。 该化合物可用于治疗增殖性疾病。
Abstract:
Compounds and a method of synthesis of compounds of formula (Ia) or (Ib): and salts, solvates, and chemically protected forms thereof, wherein the dotted lines indicate the optional presence of a double bond between C1 and C2 or C2 and C3; R 2 and R 3 are independently selected from -H, =O, =CH 2 , -CN, -R, OR, halo, =CH-R, O-SO 2 -R, CO 2 R and COR; R 10 is a carbamate-based nitrogen protecting group; and R 11 is an oxygen protecting group.
Abstract translation:化合物和式(Ia)或(Ib)化合物的合成方法及其盐,溶剂合物和化学保护形式,其中虚线表示C1和C2或C2和C3之间任选存在双键; R 2和R 3独立地选自-H,= O,= CH 2,-CN,-R,OR,卤素,= CH-R,O-SO 2 -R,CO 2 R和COR; R 10是氨基甲酸酯基氮保护基; R 11为氧保护基。
Abstract:
A compound of formula (I): or solvate thereof, wherein n is 1 to 10, and M and M' are independently selected from monovalent pharmaceutically acceptable cations, or together represent a divalent pharmaceutically acceptable cation.
Abstract:
A pixel structure (10), which forms one element of a focal plane array, includes a bolometer having a detector (20) and an insulator (14). The detector (20) is made from a material that absorbs incident thermal radiation and has an electrical resistance that varies in response to changes in the temperature of the material. The insulator (14) has a plurality of serpentine legs disposed completely underneath die detector (20) so that insulator (14) extends between the detector (20) and the substrate (12). And the insulator (14) supports the detector (20) in a spaced-apart relationship with respect to the substrate (12) to thermally isolate the detector (10) from the substrate (12). To further improve the performance of the bolometer, the bolometer includes a resonant layer (18) between the detector (10) and the insulator (14). The resonant layer is disposed such that areas defined between the detector (20) and the resonant layer (18), and between the resonant layer (18) and the insulator (14), form first and second resonant cavities, respectively.
Abstract:
Compounds of formula (Ia) and (Ib) wherein A is CH2, or a single bond; R2 is selected from: R, OH, OR, CO2H, CO2R, COH, COR, SO2R, CN; R6, R7 and R9 are independently selected from H, R, OH, OR, halo, amino, NHR, nitro, Me3Sn; and R8 is selected from H, R, OH, OR, halo, amino, NHR, nitro, Me3Sn, where R is as defined above, or the compound is a dimer with each monomer being the same or different and being of formula (Ia) or (Ib), where the R8 groups of the monomers form together a bridge having the formula -X-R'-X- linking the monomers, where R' is an alkylene chain containing from 3 to 12 carbon atoms, which chain may be interrupted by one or more hetero-atoms and/or aromatic rings and may contain one or more carbon-carbon double or triple bonds, and each X is independently selected from O, S, or N; except that in a compound of formula (Ia) when A is a single bond, then R2 is not CH=CH(CONH2) or CH=CH(CONMe2). Other related compounds are also disclosed.
Abstract:
Compounds of formula (Ia) and (Ib) wherein A is CH2, or a single bond; R2 is selected from: R, OH, OR, CO2H, CO2R, COH, COR, SO2R, CN; R6, R7 and R9 are independently selected from H, R, OH, OR, halo, amino, NHR, nitro, Me3Sn; and R8 is selected from H, R, OH, OR, halo, amino, NHR, nitro, Me3Sn, where R is as defined above, or the compound is a dimer with each monomer being the same or different and being of formula (Ia) or (Ib), where the R8 groups of the monomers form together a bridge having the formula -X-R'-X- linking the monomers, where R' is an alkylene chain containing from 3 to 12 carbon atoms, which chain may be interrupted by one or more hetero-atoms and/or aromatic rings and may contain one or more carbon-carbon double or triple bonds, and each X is independently selected from O, S, or N; except that in a compound of formula (Ia) when A is a single bond, then R2 is not CH=CH(CONH2) or CH=CH(CONMe2). Other related compounds are also disclosed.
Abstract:
Site-specific antibody-drug conjugates are described, in particular conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, allows for improved safety and efficacy of the ADC.
Abstract:
The present disclosure relates to humanized anti-Axl antibodies and conjugates thereof. Conjugates comprising pyrroiobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody are described.
Abstract:
Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody that binds CD19 and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antiobody moiety, allows for improved safety and efficacy of the ADC.